IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+0.65%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$560M
AUM Growth
-$112M
(-17%)
Cap. Flow
-$91.2M
Cap. Flow
% of AUM
-16.29%
Top 10 Holdings %
Top 10 Hldgs %
31.32%
Holding
256
New
15
Increased
27
Reduced
51
Closed
40
Top Buys
| 1 |
Biogen
BIIB
|
$41.6M |
| 2 |
CRISPR Therapeutics
CRSP
|
$16.9M |
| 3 |
Alector
ALEC
|
$8.69M |
| 4 |
Cullinan Oncology
CGEM
|
$7.59M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$6.31M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$27.4M |
| 2 |
IMAB
I-MAB
IMAB
|
$17.1M |
| 3 |
Curis
CRIS
|
$13.8M |
| 4 |
Prothena Corp
PRTA
|
$11M |
| 5 |
Celldex Therapeutics
CLDX
|
$7.72M |
Sector Composition
| 1 | Healthcare | 96.31% |
| 2 | Technology | 0.53% |
| 3 | Consumer Staples | 0.24% |
| 4 | Financials | 0.14% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Beam Therapeutics
BEAM
$1.88B
| – | – |
0
| – | – |
|
252
Bausch Health
BHC
$2.66B
| – | – |
0
| – | – |
|
|
BPMC
253
DELISTED
Blueprint Medicines
BPMC
| – | – |
0
| – | – |
|
254
Nuvation Bio
NUVB
$1.16B
| – | – |
-250,000
| Closed | -$2.61M |
|
255
argenx
ARGX
$45B
| – | – |
0
| – | – |
|
256
ARK Innovation ETF
ARKK
$7.43B
| – | – |
0
| – | – |
|